Dr. David DeLurgio, MD
Claim this profileEmory Saint Joseph's Hospital
Studies Atrial Fibrillation
Studies Stroke
7 reported clinical trials
9 drugs studied
Affiliated Hospitals
Clinical Trials David DeLurgio, MD is currently running
RF Ablation
for Atrial Fibrillation
The primary objective of CONVERGE PAS is to evaluate clinical outcomes (peri-procedural and long-term) in a cohort of patients treated during commercial use of the EPi-Sense® Guided Coagulation System or EPi-Sense ST™ Coagulation System to treat symptomatic long-standing persistent atrial fibrillation (AF) patients who are refractory or intolerant to at least one Class I and/or III AAD.
Recruiting1 award N/A
Left Atrial Appendage Occlusion vs. NOAC
for Atrial Fibrillation
The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. The clinical investigation is a prospective, randomized, multicenter active control worldwide trial. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device ("Device Group") and a commercially available NOAC medication ("Control Group"). The choice of NOAC in the Control Group will be left to study physician discretion.
Recruiting1 award N/A8 criteria
More about David DeLurgio, MD
Clinical Trial Related1 year of experience running clinical trials · Led 7 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments David DeLurgio, MD has experience with
- EPi-Sense Guided Coagulation System
- FARAPULSE Pulsed Field Ablation System
- RadioFrequency And Cryoballoon Ablation
- FARAPULSE Ablation System
- Medtronic PulseSelect Pulsed Field Ablation (PFA) System
- WATCHMAN FLX LAAC Device
Breakdown of trials David DeLurgio, MD has run
Atrial Fibrillation
Stroke
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does David DeLurgio, MD specialize in?
David DeLurgio, MD focuses on Atrial Fibrillation and Stroke. In particular, much of their work with Atrial Fibrillation has involved treating patients, or patients who are undergoing treatment.
Is David DeLurgio, MD currently recruiting for clinical trials?
Yes, David DeLurgio, MD is currently recruiting for 2 clinical trials in Atlanta Georgia. If you're interested in participating, you should apply.
Are there any treatments that David DeLurgio, MD has studied deeply?
Yes, David DeLurgio, MD has studied treatments such as EPi-Sense Guided Coagulation System, FARAPULSE Pulsed Field Ablation System, RadioFrequency and Cryoballoon Ablation.
What is the best way to schedule an appointment with David DeLurgio, MD?
Apply for one of the trials that David DeLurgio, MD is conducting.
What is the office address of David DeLurgio, MD?
The office of David DeLurgio, MD is located at: Emory Saint Joseph's Hospital, Atlanta, Georgia 30322 United States. This is the address for their practice at the Emory Saint Joseph's Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.